These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20196179)

  • 1. Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone.
    Riedel M; Schennach-Wolff R; Musil R; Dehning S; Cerovecki A; Opgen-Rhein M; Matz J; Seemüller F; Obermeier M; Engel RR; Müller N; Möller HJ; Spellmann I
    Hum Psychopharmacol; 2010 Mar; 25(2):116-25. PubMed ID: 20196179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
    Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.
    Riedel M; Spellmann I; Strassnig M; Douhet A; Dehning S; Opgen-Rhein M; Valdevit R; Engel RR; Kleindienst N; Müller N; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):360-70. PubMed ID: 17629731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A; Ritsner MS
    Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
    Akdede BB; Anil Yağcioğlu AE; Alptekin K; Turgut TI; Tümüklü M; Yazici MK; Jayathilake K; Tunca Z; Göğüş A; Meltzer HY
    J Clin Psychiatry; 2006 Dec; 67(12):1912-9. PubMed ID: 17194269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: a naturalistic 12-month follow-up study.
    Guo X; Zhai J; Wei Q; Twamley EW; Jin H; Fang M; Hu M; Zhao J;
    Neurosci Lett; 2011 Oct; 503(2):141-6. PubMed ID: 21888948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits.
    Chouinard S; Stip E; Poulin J; Melun JP; Godbout R; Guillem F; Cohen H
    Curr Med Res Opin; 2007 Mar; 23(3):575-83. PubMed ID: 17355738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine.
    Delle Chiaie R; Salviati M; Fiorentini S; Biondi M
    Exp Clin Psychopharmacol; 2007 Dec; 15(6):563-8. PubMed ID: 18179309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of aripiprazole on cognition in the treatment of patients with schizophrenia.
    Riedel M; Spellmann I; Schennach-Wolff R; Musil R; Dehning S; Cerovecki A; Opgen-Rhein M; Matz J; Seemüller F; Obermeier M; Severus E; Engel RR; Müller N; Möller HJ
    Pharmacopsychiatry; 2010 Mar; 43(2):50-7. PubMed ID: 20336597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Open, randomized trial of the effects of aripiprazole versus risperidone on social cognition in schizophrenia.
    Maat A; Cahn W; Gijsman HJ; Hovens JE; Kahn RS; Aleman A
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):575-84. PubMed ID: 24418213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia.
    Riedel M; Müller N; Spellmann I; Engel RR; Musil R; Valdevit R; Dehning S; Douhet A; Cerovecki A; Strassnig M; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2007 Oct; 257(7):402-12. PubMed ID: 17629725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive effects of six months of treatment with quetiapine in antipsychotic-naïve first-episode schizophrenia.
    Andersen R; Fagerlund B; Rasmussen H; Ebdrup BH; Aggernaes B; Gade A; Oranje B; Glenthoj B
    Psychiatry Res; 2011 May; 187(1-2):49-54. PubMed ID: 21075453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder.
    Schennach-Wolff R; Meyer S; Seemüller F; Jäger M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Möller HJ; Riedel M
    J Psychiatr Res; 2011 Dec; 45(12):1639-47. PubMed ID: 21862035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normalizing effects of EVP-6124, an α-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia.
    Preskorn SH; Gawryl M; Dgetluck N; Palfreyman M; Bauer LO; Hilt DC
    J Psychiatr Pract; 2014 Jan; 20(1):12-24. PubMed ID: 24419307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of dopamine partial agonists on the nicotine dependency in patients with schizophrenia.
    Kim SH; Han DH; Joo SY; Min KJ
    Hum Psychopharmacol; 2010 Mar; 25(2):187-90. PubMed ID: 20033907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in cognitive function associated with syndrome changes on two five-factor models of the Positive and Negative Syndrome Scale.
    Jerrell JM; Hrisko S
    Hum Psychopharmacol; 2012 Nov; 27(6):566-76. PubMed ID: 23817989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).
    Davidson M; Galderisi S; Weiser M; Werbeloff N; Fleischhacker WW; Keefe RS; Boter H; Keet IP; Prelipceanu D; Rybakowski JK; Libiger J; Hummer M; Dollfus S; López-Ibor JJ; Hranov LG; Gaebel W; Peuskens J; Lindefors N; Riecher-Rössler A; Kahn RS
    Am J Psychiatry; 2009 Jun; 166(6):675-82. PubMed ID: 19369319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.